We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Angelman Syndrome

News List

Ipsen and Exicure to develop therapies for neurodegenerative disorders pharmaceutical-technology
August 04, 2021
Ipsen and Exicure have entered an exclusive partnership agreement for the research, development and marketing of new spherical nucleic acids (SNAs) for the potential treatment of Huntington’s disease and Angelman syndrome.
Ovid and UConn Enter Strategic Research Collaboration contractpharma
July 24, 2020
Aim to accelerate the development of next-gen genetic therapy for Angelman Syndrome.
Ovid, Angelini Pharma Enter Exclusive License Agreement contractpharma
July 14, 2020
To develop, manufacture and commercialize OV101 for the treatment of Angelman Syndrome in Europe.